IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -694 Thousand USD | -60.79% |
| 2022 | -908 Thousand USD | -25.94% |
| 2021 | -721 Thousand USD | -1176.12% |
| 2020 | 67 Thousand USD | -90.97% |
| 2019 | 742 Thousand USD | -59.32% |
| 2018 | 1.82 Million USD | -62.17% |
| 2017 | 4.82 Million USD | -1.61% |
| 2016 | 4.9 Million USD | 5.13% |
| 2015 | 4.66 Million USD | 191.74% |
| 2014 | 1.59 Million USD | 68.57% |
| 2013 | 948 Thousand USD | -21.52% |
| 2012 | 1.2 Million USD | 174.55% |
| 2011 | 440 Thousand USD | -67.09% |
| 2010 | 1.33 Million USD | 4.56% |
| 2009 | 1.27 Million USD | 30.93% |
| 2008 | 976.61 Thousand USD | 16.9% |
| 2007 | 835.41 Thousand USD | 214.18% |
| 2006 | 265.9 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -512 Thousand USD | -5.44% |
| 2023 Q2 | -304 Thousand USD | 1.94% |
| 2023 Q3 | 35 Thousand USD | 111.51% |
| 2023 FY | -1.46 Million USD | -60.79% |
| 2023 Q4 | -294 Thousand USD | -940.0% |
| 2023 Q1 | -310 Thousand USD | -1.97% |
| 2022 Q1 | -233 Thousand USD | -42.07% |
| 2022 FY | -908 Thousand USD | -25.94% |
| 2022 Q2 | -84 Thousand USD | 63.95% |
| 2022 Q3 | -287 Thousand USD | -241.67% |
| 2022 Q4 | -304 Thousand USD | -5.92% |
| 2021 Q1 | -335 Thousand USD | -194.37% |
| 2021 FY | -721 Thousand USD | -1176.12% |
| 2021 Q2 | -316 Thousand USD | 5.67% |
| 2021 Q4 | -164 Thousand USD | -274.47% |
| 2021 Q3 | 94 Thousand USD | 129.75% |
| 2020 Q4 | 355 Thousand USD | 33.46% |
| 2020 Q3 | 266 Thousand USD | 195.68% |
| 2020 Q1 | -276 Thousand USD | -505.88% |
| 2020 FY | 67 Thousand USD | -90.97% |
| 2020 Q2 | -278 Thousand USD | -0.72% |
| 2019 Q1 | 416 Thousand USD | -36.1% |
| 2019 Q4 | 68 Thousand USD | 11.48% |
| 2019 Q3 | 61 Thousand USD | 102.85% |
| 2019 Q2 | -2.14 Million USD | -614.66% |
| 2019 FY | 742 Thousand USD | -59.32% |
| 2018 Q3 | 700 Thousand USD | 199.15% |
| 2018 Q2 | 234 Thousand USD | -2.09% |
| 2018 Q1 | 239 Thousand USD | -82.52% |
| 2018 FY | 1.82 Million USD | -62.17% |
| 2018 Q4 | 651 Thousand USD | -7.0% |
| 2017 Q4 | 1.36 Million USD | 18.15% |
| 2017 FY | 4.82 Million USD | -1.61% |
| 2017 Q3 | 1.15 Million USD | 11.57% |
| 2017 Q2 | 1.03 Million USD | -17.76% |
| 2017 Q1 | 1.26 Million USD | -30.71% |
| 2016 Q2 | 606 Thousand USD | -19.52% |
| 2016 Q4 | 1.82 Million USD | 5.69% |
| 2016 FY | 4.9 Million USD | 5.13% |
| 2016 Q3 | 1.72 Million USD | 184.16% |
| 2016 Q1 | 753 Thousand USD | -44.67% |
| 2015 FY | 4.66 Million USD | 191.74% |
| 2015 Q4 | 1.36 Million USD | -37.97% |
| 2015 Q2 | 566 Thousand USD | 4.62% |
| 2015 Q1 | 541 Thousand USD | -29.19% |
| 2015 Q3 | 2.19 Million USD | 287.63% |
| 2014 Q2 | 160 Thousand USD | -27.93% |
| 2014 FY | 1.59 Million USD | 68.57% |
| 2014 Q4 | 764 Thousand USD | 69.03% |
| 2014 Q3 | 452 Thousand USD | 182.5% |
| 2014 Q1 | 222 Thousand USD | 54.17% |
| 2013 Q4 | 144 Thousand USD | 44.0% |
| 2013 FY | 948 Thousand USD | -21.52% |
| 2013 Q3 | 100 Thousand USD | -81.72% |
| 2013 Q2 | 547 Thousand USD | 248.41% |
| 2013 Q1 | 157 Thousand USD | -85.46% |
| 2012 Q3 | 3000.00 USD | -85.71% |
| 2012 Q4 | 1.08 Million USD | 35900.0% |
| 2012 FY | 1.2 Million USD | 174.55% |
| 2012 Q1 | 285 Thousand USD | 4.78% |
| 2012 Q2 | 21 Thousand USD | -92.63% |
| 2011 Q1 | 98 Thousand USD | -20.33% |
| 2011 Q2 | 46 Thousand USD | -53.06% |
| 2011 Q4 | 272 Thousand USD | 1033.33% |
| 2011 Q3 | 24 Thousand USD | -47.83% |
| 2011 FY | 440 Thousand USD | -67.09% |
| 2010 Q2 | 126 Thousand USD | -30.77% |
| 2010 Q1 | 182 Thousand USD | -6.14% |
| 2010 FY | 1.33 Million USD | 4.56% |
| 2010 Q3 | 906 Thousand USD | 619.05% |
| 2010 Q4 | 123 Thousand USD | -86.42% |
| 2009 Q2 | 500.4 Thousand USD | 148.96% |
| 2009 Q3 | 383.4 Thousand USD | -23.38% |
| 2009 Q1 | 201 Thousand USD | -15.66% |
| 2009 FY | 1.27 Million USD | 30.93% |
| 2009 Q4 | 193.9 Thousand USD | -49.43% |
| 2008 Q4 | 238.33 Thousand USD | -15.54% |
| 2008 Q1 | 144.99 Thousand USD | -44.36% |
| 2008 Q2 | 298 Thousand USD | 105.52% |
| 2008 Q3 | 282.17 Thousand USD | -5.31% |
| 2008 FY | 976.61 Thousand USD | 16.9% |
| 2007 Q2 | 335.92 Thousand USD | 284.11% |
| 2007 Q3 | 178.73 Thousand USD | -46.79% |
| 2007 Q4 | 260.61 Thousand USD | 45.81% |
| 2007 FY | 835.41 Thousand USD | 214.18% |
| 2007 Q1 | 87.45 Thousand USD | 45.96% |
| 2006 Q3 | 3970.00 USD | -94.91% |
| 2006 Q4 | 59.91 Thousand USD | 1409.24% |
| 2006 FY | 265.9 Thousand USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q2 | 77.96 Thousand USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| HST Global, Inc. | - USD | Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 493.068% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -2293.103% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 101.724% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| MultiCell Technologies, Inc. | 49.32 USD | 1407237.064% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | -28354.285% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -13914.54% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -706.714% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 97.31% |
| SQZ Biotechnologies Company | 9.79 Million USD | 107.086% |
| Resverlogix Corp. | - USD | Infinity% |
| Neon Bloom, Inc. | - USD | Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -7736.495% |
| Mesoblast Limited | -35.16 Million USD | 98.027% |
| GB Sciences, Inc. | -624.00 USD | -111117.949% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 493.068% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 105.929% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 1091.429% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 243.854% |
| ContraFect Corporation | -154 Thousand USD | -350.649% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -79.096% |
| BioStem Technologies, Inc. | 15.42 Million USD | 104.499% |
| LadRx Corporation | -11.83 Thousand USD | -5763.963% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 593.95% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.009% |
| Biomind Labs Inc. | -15.42 Thousand USD | -4399.481% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 269.2% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 100.583% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -117.21% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 104.627% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 22472.663% |
| GeneThera, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 102.456% |
| Adynxx, Inc. | - USD | Infinity% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -1932.211% |
| Marizyme, Inc. | 457.7 Thousand USD | 251.627% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -6209.091% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 254.207% |
| Zenith Capital Corp. | - USD | Infinity% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 1155.867% |
| Halberd Corporation | -208.00 USD | -333553.846% |
| Genus plc | 178.7 Million USD | 100.388% |
| Pharming Group N.V. | 220.1 Million USD | 100.315% |
| MetaStat, Inc. | - USD | Infinity% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 1215.289% |
| IMV Inc. | -962.29 Thousand USD | 27.881% |
| Affymax, Inc. | 1.35 Million USD | 151.137% |
| SYBLEU INC | 11.69 Thousand USD | 6033.653% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Enzolytics Inc. | 30.7 Thousand USD | 2359.997% |
| argenx SE | 1.1 Billion USD | 100.063% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 212.41% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 1004.105% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| Cell Source, Inc. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | 1519.223% |
| Q BioMed Inc. | -8988.00 USD | -7621.406% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 107.221% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -1288.0% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 101.565% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 39.207% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 170.244% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -458.547% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -727.678% |
| ONE Bio Corp. | 20.12 Million USD | 103.448% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -611.685% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -34.886% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | -10.135% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -1338.074% |
| NovAccess Global Inc. | - USD | Infinity% |
| Itoco Inc. | - USD | Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 100.169% |
| International Stem Cell Corporation | 4.6 Million USD | 115.061% |
| Bioxytran, Inc. | -8285.00 USD | -8276.584% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -86.059% |
| Neutra Corp. | 14.33 Thousand USD | 4941.298% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -746.341% |
| PureTech Health plc | -1.6 Million USD | 56.706% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 30.686% |
| IXICO plc | 3.27 Million USD | 121.223% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 61.251% |
| CSL Limited | 7.7 Billion USD | 100.009% |
| Cellectis S.A. | 18 Thousand USD | 3955.556% |